GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Total Liabilities

Ascentage Pharma Group International (FRA:36X) Total Liabilities : €298.4 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Total Liabilities?

Ascentage Pharma Group International's Total Liabilities for the quarter that ended in Jun. 2024 was €298.4 Mil.

Ascentage Pharma Group International's quarterly Total Liabilities increased from Jun. 2023 (€298.74 Mil) to Dec. 2023 (€312.05 Mil) but then declined from Dec. 2023 (€312.05 Mil) to Jun. 2024 (€298.45 Mil).

Ascentage Pharma Group International's annual Total Liabilities increased from Dec. 2021 (€236.95 Mil) to Dec. 2022 (€327.90 Mil) but then declined from Dec. 2022 (€327.90 Mil) to Dec. 2023 (€312.05 Mil).


Ascentage Pharma Group International Total Liabilities Historical Data

The historical data trend for Ascentage Pharma Group International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Total Liabilities Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 40.37 111.17 236.95 327.90 312.05

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 304.92 327.90 298.74 312.05 298.45

Ascentage Pharma Group International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ascentage Pharma Group International's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=119.974+(151.441+40.634
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=312.0

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=321.12-9.071
=312.0

Ascentage Pharma Group International's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=136.423+(124.284+37.742
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=298.4

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=397.876-99.427
=298.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines